Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications
Authors
Keywords
-
Journal
Expert Review of Respiratory Medicine
Volume 10, Issue 1, Pages 53-68
Publisher
Informa UK Limited
Online
2015-11-17
DOI
10.1586/17476348.2016.1115349
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
- (2015) P A Jänne et al. BRITISH JOURNAL OF CANCER
- The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis
- (2015) Yaxiong Zhang et al. MEDICAL ONCOLOGY
- Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
- (2014) A. W. Tolcher et al. CLINICAL CANCER RESEARCH
- Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy
- (2014) Mihaly Cserepes et al. EUROPEAN JOURNAL OF CANCER
- The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma
- (2014) Benjamin Izar et al. Journal of Thoracic Oncology
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- The prognostic and predictive value ofKRASoncogene substitutions in lung adenocarcinoma
- (2013) Liza C. Villaruz et al. CANCER
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
- (2013) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Response to First-Line Chemotherapy in Patients With Non–Small-Cell Lung Cancer According to Epidermal Growth Factor Receptor and K-RAS Mutation Status
- (2013) Xiaopeng Dong et al. Clinical Lung Cancer
- Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non–Small-Cell Lung Cancer Segregated According to KRAS Mutation Status
- (2013) Giulio Metro et al. Clinical Lung Cancer
- Selumetinib: a promising pharmacologic approach forKRAS-mutant advanced non-small-cell lung cancer
- (2013) Giulio Metro et al. Future Oncology
- Pooled Analysis of the Prognostic and Predictive Effects ofKRASMutation Status andKRASMutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
- (2013) Frances A. Shepherd et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis
- (2013) Daquan Meng et al. LUNG CANCER
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Signaling through cyclin D-dependent kinases
- (2013) Y J Choi et al. ONCOGENE
- Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
- (2013) Jong-Mu Sun et al. PLoS One
- The mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance
- (2013) Taro Ohba et al. SURGERY TODAY
- Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation
- (2012) Qi Sun et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
- (2012) S V Holt et al. BRITISH JOURNAL OF CANCER
- Association ofKRASandEGFRmutations with survival in patients with advanced lung adenocarcinomas
- (2012) Melissa L. Johnson et al. CANCER
- Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas
- (2012) Paul K. Paik et al. CANCER
- Opening a New GATAway for Treating KRAS-Driven Lung Tumors
- (2012) Mariano Barbacid CANCER CELL
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
- (2012) Madhu S. Kumar et al. CELL
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
- (2012) S. Dogan et al. CLINICAL CANCER RESEARCH
- Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort
- (2012) Chiara Scoccianti et al. EUROPEAN RESPIRATORY JOURNAL
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype
- (2012) Giulio Metro et al. LUNG CANCER
- Abstract B225: A phase I dose-escalation study of selumetinib in combination with docetaxel in patients with advanced solid tumors.
- (2012) K. Kim et al. MOLECULAR CANCER THERAPEUTICS
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
- (2012) Zhao Chen et al. NATURE
- Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
- (2012) T. Maurer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
- (2011) M. C. Garassino et al. ANNALS OF ONCOLOGY
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
- (2011) L. V. Sequist et al. ANNALS OF ONCOLOGY
- Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
- (2011) F Morgillo et al. BRITISH JOURNAL OF CANCER
- Mechanisms of Ras membrane organization and signaling: Ras on a rocker
- (2011) Daniel Abankwa et al. CELL CYCLE
- A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
- (2011) Gregory J. Riely et al. Journal of Thoracic Oncology
- Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma
- (2011) Patrick L. Wagner et al. LUNG CANCER
- KRAS mutant allele-specific imbalance in lung adenocarcinoma
- (2011) Simion I Chiosea et al. MODERN PATHOLOGY
- Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling
- (2011) J. E. Chaft et al. MOLECULAR CANCER THERAPEUTICS
- An orthosteric inhibitor of the Ras-Sos interaction
- (2011) Anupam Patgiri et al. Nature Chemical Biology
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
- (2010) J. R. Dry et al. CANCER RESEARCH
- The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
- (2010) U. Banerji et al. CLINICAL CANCER RESEARCH
- Sex differences in lung cancer susceptibility: A review
- (2010) Chikako Kiyohara et al. Gender Medicine
- Allosteric Modulation of Ras-GTP Is Linked to Signal Transduction through RAF Kinase
- (2010) Greg Buhrman et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study
- (2010) Claus-Peter Schneider et al. Journal of Thoracic Oncology
- Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma
- (2010) Takayuki Kosaka et al. Journal of Thoracic Oncology
- A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
- (2010) John D. Hainsworth et al. Journal of Thoracic Oncology
- Evaluation of Kras Gene Mutation and Copy Number Gain in Non-small Cell Lung Cancer
- (2010) Hidefumi Sasaki et al. Journal of Thoracic Oncology
- Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non-Small Cell Lung Cancer Cell Lines
- (2010) E. B. Garon et al. MOLECULAR CANCER THERAPEUTICS
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
- (2010) S. A. Forbes et al. NUCLEIC ACIDS RESEARCH
- KRAS gene mutations in lung cancer: Particulars established and issues unresolved
- (2010) Koji Okudela et al. PATHOLOGY INTERNATIONAL
- Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo
- (2010) Jieru Meng et al. PLoS One
- Allosteric modulation of Ras positions Q61 for a direct role in catalysis
- (2010) G. Buhrman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- In Situ Evidence of KRAS Amplification and Association With Increased p21 Levels in Non–Small Cell Lung Carcinoma
- (2009) Patrick L. Wagner et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
- (2009) Claudia Scholl et al. CELL
- Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas
- (2009) Tetsukan Woo et al. LUNG CANCER
- Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status
- (2009) Aristea Kalikaki et al. LUNG CANCER
- KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
- (2009) Chen Mao et al. LUNG CANCER
- Oncogenic Activating Mutations Are Associated with Local Copy Gain
- (2009) B. Modrek et al. MOLECULAR CANCER RESEARCH
- Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: Etiopathogenic similarities, differences and paradoxes
- (2009) Miquel Porta et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
- (2009) Junichi Soh et al. PLoS One
- Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance
- (2008) N. T. Ihle et al. CANCER RESEARCH
- Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
- (2008) G. J. Riely et al. CLINICAL CANCER RESEARCH
- Farnesyltransferase Inhibitors: A Detailed Chemical View on an Elusive Biological Problem
- (2008) Sergio Sousa et al. CURRENT MEDICINAL CHEMISTRY
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- (2008) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now